The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Pathological Tumor-Node-Metastasis (pTNM) Staging for Papillary and Follicular Thyroid Carcinomas: A Retrospective Analysis of 700 Patients
Open accessAbstract
The TNM classification (tumor-node-metastasis) was adopted by the American Joint Committee on Cancer and the International Union against Cancer a decade ago to avoid heterogeneity of prognostic classification schemes used for differentiated thyroid cancers. To date, however, clinical data based on this classification are lacking. We retrospectively evaluate the prognosis of 700 patients (208 men and 492 women) with papillary (89%) and follicular (11%) thyroid cancers according to the pathological TNM (pTNM) staging system, treated over a 25-yr period (1970-1995). Patients who received primary treatment at our center constituted 87.4% of the cases; the majority underwent total thyroidectomy, followed by 131I ablative therapy in high risk groups, as standard treatment. Clinical and follow-up data were obtained from the medical records and our cancer registry. Disease-free and cancer-specific survival data were analyzed by Kaplan-Meier product limit estimates and Cox proportional hazard models. Patient distribution by the pTNM system were: stage I, 516 patients; stage II, 57 patients; stage III, 104 patients; and stage IV, 23 patients. Over a mean +/- SE follow-up of 11.3 +/- 0.3 yr, the overall cancer recurrence and mortality rates were 20.5% and 8.4%, respectively. However, the respective cancer recurrence and mortality rates were distinctly different in the various pTNM stages: 15.4% and 1.7% in stage I, 22% and 15.8% in stage II, 46.4% and 30% in stage III, and 66.7% and 60.9% in stage IV tumors. Using actuarial survival plots, a clear separation in both disease-free survival and cancer-specific survival was noted among all the stages (P < 0.0001). Risk factors analyses showed a significant association between all the prognostic variables used in TNM staging (age, tumor size, extent of primary tumor, and presence of nodal or distant metastases) and the observed end points of recurrence or death from thyroid cancer. After correcting for TNM stages, the risk of cancer recurrence was halved in female compared to male patients, whereas this was 1.7-fold higher in multifocal than unifocal tumors. Conversely, cancer mortality was 3.4-fold higher in follicular than papillary thyroid cancer. In the analysis of effect of primary treatment among 492 patients with tumor more advanced than the T1N0M0 category, patients who underwent less extensive surgery (lobectomy or subtotal thyroidectomy) had a 2.5-fold risk of cancer recurrence (P < 0.0001) and a 2.2-fold risk of death (P < 0.01) compared to those who underwent total or near-total thyroidectomy. Patients not treated with 131I ablation had a 2.1-fold greater risk of cancer recurrence (P < 0.0001) than those given 131I ablation, although no difference was noted in deaths from thyroid cancer. Based on our data, the pTNM classification is useful in distinguishing patients with different prognostic outcomes. However, the small patient numbers in pTNM stages other than stages I precludes us from evaluating its usefulness as a guide for therapy. Until prospective data could be accrued from controlled treatment trials, we support the standard practice of total thyroidectomy followed by 131I ablative therapy (if focal iodide uptake was noted) in patients with papillary thyroid cancer more advanced than the T1N0M0 category or of multicentric nature and in the majority of patients with follicular thyroid cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
TNM Classification of Malignant Tumours
(1987) · Springer eBooks · doi:10.1007/978-3-642-82982-6 · Cited by 16,049
Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer
Mazzaferri, E. L., & Jhiang, S. M. (1994) · The American Journal of Medicine · doi:10.1016/0002-9343(94)90321-2 · Cited by 2,635
HAY, I. D., Bergstralh, E. J., Goellner, J. R., Ebersold, J. R., & Grant, C. S. (1993) · PubMed · Cited by 1,223
Natural History, Treatment, and Course of Papillary Thyroid Carcinoma*
DEGROOT, L. J., KAPLAN, E. L., MCCORMICK, M., & STRAUS, F. H. (1990) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-71-2-414 · Cited by 1,049
An expanded view of risk-group definition in differentiated thyroid carcinoma.
Cady, B., & Rossi, R. (1988) · PubMed · Cited by 937
HAY, I. D., Grant, C. S., Taylor, W. F., & McConahey, W. M. (1987) · PubMed · Cited by 828
Gilliland, F. D., Hunt, W. C., Morris, D. M., & Key, C. R. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970201)79:3<564::aid-cncr20>3.0.co;2-0 · Cited by 803
Papillary thyroid carcinoma: A 10 year foliow-up report of the impact of therapy in 576 patients
Mazzaferri, E. L., & Young, R. L. (1981) · The American Journal of Medicine · doi:10.1016/0002-9343(81)90573-8 · Cited by 670
Hay, I. D. (1990) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(18)30310-4 · Cited by 634
A prognostic index for thyroid carcinoma. A study of the E.O.R.T.C. thyroid cancer cooperative group
Byar, D. P., Green, S. B., Dor, P., Williams, E. D., Colon, J., van Gilse, H. A., Mayer, M., Sylvester, R. J., & Van Glabbeke, M. (1979) · European Journal of Cancer (1965) · doi:10.1016/0014-2964(79)90291-3 · Cited by 554
Thyroid Cancer Nodal Metastases: Biologic Significance and Therapeutic Considerations
Grebe, S. K. G., & Hay, I. D. (1996) · Surgical Oncology Clinics of North America · doi:10.1016/s1055-3207(18)30404-6 · Cited by 387
Papillary and follicular thyroid cancer
Simpson, W. J., McKinney, S. E., Carruthers, J. S., Gospodarowicz, M. K., Sutcliffe, S. B., & Panzarella, T. (1987) · The American Journal of Medicine · doi:10.1016/0002-9343(87)90758-3 · Cited by 382
Treatment Guidelines for Patients With Thyroid Nodules and Well-Differentiated Thyroid Cancer
Singer, P. A. (1996) · Archives of Internal Medicine · doi:10.1001/archinte.1996.00440180017002 · Cited by 349
Papillary and follicular thyroid cancer: Impact of treatment in 1578 patients
Simpson, W. J., Panzarella, T., Carruthers, J. S., Gospodarowicz, M. K., & Sutcliffe, S. B. J. (1988) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(88)90381-1 · Cited by 275
Prognostic factors and risk group analysis in follicular carcinoma of the thyroid
Shaha, A. R., Loree, T. R., & Shah, J. P. (1995) · Surgery · doi:10.1016/s0039-6060(05)80124-2 · Cited by 273
Papillary thyroid carcinoma: factors influencing prognosis and current therapy.
Mazzaferri, E. L. (1987) · PubMed · Cited by 243
Risk group stratification and prognostic factors in papillary carcinoma of thyroid
Shaha, A. R., Shah, J. P., & Loree, T. R. (1996) · Annals of Surgical Oncology · doi:10.1007/bf02306085 · Cited by 199
Does the method of management of papillary thyroid carcinoma make a difference in outcome?
DeGroot, L. J., Kaplan, E. L., Straus, F. H., & Shukla, M. S. (1994) · World Journal of Surgery · doi:10.1007/bf00348202 · Cited by 136
Cited by
Haugen, B. R., Alexander, E. K., Bible, K. C., Doherty, G. M., Mandel, S. J., Nikiforov, Y. E., Pacini, F., Randolph, G. W., Sawka, A. M., Schlumberger, M., et al. (2016) · Thyroid® · doi:10.1089/thy.2015.0020 · Cited by 16,535
Cooper, D. S., Doherty, G. M., Haugen, B. R., Kloos, R. T., Lee, S. L., Mandel, S. J., Mazzaferri, E. L., McIver, B., Pacini, F., Schlumberger, M., et al. (2009) · Thyroid · doi:10.1089/thy.2009.0110 · Cited by 6,707
“Application of the AJCC=International Union against Cancer (AJCC=UICC) classification system based on pTNM parameters and age is recommended for tumors of all types, including thyroid cancer (121,190), because it provides a useful shorthand method to describe the extent of the tumor (191) (Table 4).”
Cooper, D. S., Doherty, G. M., Haugen, B. R., Kloos, R. T., Lee, S. L., Mandel, S. J., Mazzaferri, E. L., McIver, B., Sherman, S. I., & Tuttle, R. M. (2006) · Thyroid · doi:10.1089/thy.2006.16.109 · Cited by 2,016
Guidelines for the management of thyroid cancer
Perros, P., Boelaert, K., Colley, S., Evans, C., Evans, R. M., Gerrard BA, G., Gilbert, J., Harrison, B., Johnson, S. J., Giles, T. E., et al. (2014) · Clinical Endocrinology · doi:10.1111/cen.12515 · Cited by 1,372
Chow, S., Law, S. C. K., Chan, J. K. C., Au, S., Yau, S., & Lau, W. (2003) · Cancer · doi:10.1002/cncr.11442 · Cited by 723
Metadata
- Authors
- Loh, K.-C.
- Venue
- Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1997-11-01
- Volume
- 82
- Issue
- 11
- Pages
- 3553-3562
- ISSN
- 0021-972X (ISSN-L)
- OpenAlex
- W2027254461
- Cited by
- 396
- References
- 20
- FWCI
- 5.97
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.